.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Lung Cancer

The AJMC^® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Oncology Care Pathways Supporting the Use of High-value Treatments for NSCLC

This AJMC® publication explores the value of clinical oncology care pathways in non–small cell lung cancer (NSCLC) with insights from Edward Arrowsmith, MD, Medical Director for Pathways at OneOncology in Chattanooga, Tennessee.

Dr Hatim Husain Discusses HER2, Novel Therapy Exploration in Lung Cancer

September 23rd 2022, 2:24pm

Video

During the Quality Cancer Care Alliance Summer 2022 National Leadership Summit, Hatim Husain, MD, discusses how HER2 exploration in lung cancer differs from that in breast cancer, as well as novel therapies being explored for HER2 and other disease targets.

Evolving NSCLC Treatment Landscape Following IMpower010 Trial Data

September 23rd 2022, 1:53pm

Video

IMpower010 trial data may influence a significant evolution in treatment of non–small cell lung cancer.

Phase 3 Trial Backs First-line Use of Cemiplimab With Chemotherapy in aNSCLC

September 21st 2022, 7:46pm

Article

With these new findings coming from the EMPOWER-Lung 3 trial, the anti-programmed cell death-1 inhibitor cemiplimab is now just the second of its kind to show efficacy in these patients as both monotherapy and as a combination regimen, regardless of histology.

Real-world Lung Cancer Testing Rates Are Lower Than They Should Be, Says Dr Ticiana Leal

September 14th 2022, 1:33pm

Article

Biomarker testing should be done on all patients with an initial diagnosis of advanced nonsquamous non–small cell lung cancer, but the testing rates in the real world are lower than they should be, particularly for underserved or minority populations, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.

Lung Cancer Screening Leads to Earlier Diagnosis, but Not Overdiagnosis

September 12th 2022, 10:20pm

Article

A study carried out at 4 health care systems found rates of stage I lung cancer increased, and rates of stage IV cancer decreased, once screening was initiated.

Dr Hatim Husain: NCCN Guidelines Adjust to Meet Lung Cancer Treatment Needs

September 10th 2022, 1:18pm

Video

Hatim Husain, MD, discusses how National Comprehensive Cancer Network (NCCN) treatment guidelines adjust to meet the treatment needs of patients with lung cancer.

Recommendations to Safeguard Quality Shared Decision-Making for Lung Cancer Screening

September 8th 2022, 3:00pm

Article

An updated national coverage determination from CMS about lung cancer screening has some stakeholders concerned that the quality of decision-making tools used by providers and patients may weaken.

Dr Hatim Husain: Biomarker Testing Is a Treatment Cornerstone in NSCLC

August 29th 2022, 5:07pm

Video

Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.

Clinicians Slow to Adopt PD-1, PD-L1 Inhibitors in NSCLC

August 23rd 2022, 10:42pm

Article

A significant subset of patients continues to receive chemotherapy monotherapy despite the availability of newer approaches, including programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors.

Evaluating and Integrating New Data Into NSCLC Clinical Pathways

August 18th 2022, 5:56pm

Video

Edward Arrowsmith, MD, concludes with his thoughts on developing therapies and how they are implemented into clinical pathways for NSCLC treatment.